Brainstorm Cell Therapeutics (NASDAQ:BCLI) and Alector (NASDAQ:ALEC) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, institutional ownership, risk, dividends, analyst recommendations, earnings and valuation.
Valuation and Earnings
This table compares Brainstorm Cell Therapeutics and Alector’s top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Brainstorm Cell Therapeutics||N/A||N/A||-$13.95 million||N/A||N/A|
|Alector||$27.51 million||39.63||-$52.25 million||($4.62)||-3.43|
Brainstorm Cell Therapeutics has higher earnings, but lower revenue than Alector.
This is a breakdown of current ratings and target prices for Brainstorm Cell Therapeutics and Alector, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Brainstorm Cell Therapeutics||0||0||3||0||3.00|
Brainstorm Cell Therapeutics currently has a consensus target price of $10.00, indicating a potential upside of 171.74%. Alector has a consensus target price of $26.67, indicating a potential upside of 68.35%. Given Brainstorm Cell Therapeutics’ higher possible upside, equities analysts plainly believe Brainstorm Cell Therapeutics is more favorable than Alector.
This table compares Brainstorm Cell Therapeutics and Alector’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Brainstorm Cell Therapeutics||N/A||-685.14%||-161.85%|
Insider and Institutional Ownership
11.3% of Brainstorm Cell Therapeutics shares are held by institutional investors. Comparatively, 41.1% of Alector shares are held by institutional investors. 22.6% of Brainstorm Cell Therapeutics shares are held by insiders. Comparatively, 34.4% of Alector shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Alector beats Brainstorm Cell Therapeutics on 6 of the 8 factors compared between the two stocks.
About Brainstorm Cell Therapeutics
Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of central nervous system (CNS) adult stem cell therapies designed to address the unmet medical needs of patients with debilitating neurodegenerative diseases. The company holds rights to develop and commercialize its NurOwn technology that utilizes a patient's own cells, which are engineered outside the body, to produce and secrete factors known to promote neuronal survival. It is developing NurOwn for various neurodegenerative diseases, including its lead indication, which is in Phase III clinical trial for the treatment of amyotrophic lateral sclerosis, as well as in preclinical trial for the treatment of multiple sclerosis, Parkinson's disease, Huntington's disease, and autism spectrum disorder. The company was formerly known as Golden Hand Resources Inc. and changed its name to Brainstorm Cell Therapeutics Inc. in November 2004 to reflect its new line of business in the development of novel cell therapies for neurodegenerative diseases. Brainstorm Cell Therapeutics Inc. was founded in 2000 and is headquartered in New York, New York.
Alector, Inc., a clinical stage biotechnology company, focuses on developing therapies that harness the immune system to cure neurodegenerative diseases. Its products in Phase I clinical trial include AL001, a humanized recombinant monoclonal antibody for the treatment of frontotemporal dementia; and AL002 for the treatment of Alzheimer's disease. The company's preclinical stage products comprise AL101 for the treatment of multiple neurodegenerative disorders; and AL003 for the treatment of Alzheimer's disease. It also has 10 programs under research and development stage. The company was founded in 2013 and is headquartered in South San Francisco, California.
Receive News & Ratings for Brainstorm Cell Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Brainstorm Cell Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.